AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 38509698 — intervention group
Group type: EXPERIMENTAL
Intervention: STOP-BANG questionnaire
Number of subjects: 116
Study 38509698 — intervention group
Group type: EXPERIMENTAL
Intervention: Polysomnography (PSG) for diagnosing SDB in preserved ejection fraction (EF) CHF
Number of subjects: 116
Study 38509699 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant administration of RV5 and IPV
Number of subjects: 400
Study 38509699 — intervention group
Group type: COMPARATOR
Intervention: Staggered administration of RV5 and IPV
Number of subjects: 400
Study 38510299 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymptomatic CTRCD defined by cTnT greater than the sex-specific 99th percentile URL
Number of subjects: 118
Study 38510299 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymptomatic CTRCD defined by sex-neutral cTnI
Number of subjects: 118
Study 38510299 — intervention group
Group type: EXPERIMENTAL
Intervention: End of anthracycline therapy
Number of subjects: 118
Study 38510299 — intervention group
Group type: EXPERIMENTAL
Intervention: CTRCD during adjuvant therapy
Number of subjects: 118
Study 38510323 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP)
Number of subjects: 71
Study 38510323 — intervention group
Group type: EXPERIMENTAL
Intervention: Microfragmented adipose tissue (MFAT)
Number of subjects: 71
Study 38510483 — intervention group
Group type: EXPERIMENTAL
Intervention: Holographic Memory Resolution® (HMR®)
Number of subjects: 60
Study 38510502 — intervention group
Group type: EXPERIMENTAL
Intervention: High HDL-C (>70 mg/dL)
Number of subjects: 607
Study 38510502 — intervention group
Group type: EXPERIMENTAL
Intervention: Low HDL-C (<50 mg/dL)
Number of subjects: 607
Study 38510502 — intervention group
Group type: COMPARATOR
Intervention: Average HDL-C (50-70 mg/dL)
Number of subjects: 607
Study 38510574 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth intervention (self-monitored educational intervention via an internet application on mobile devices)
Number of subjects: 300
Study 38510574 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard healthcare)
Number of subjects: 300
Study 38510574 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth intervention
Number of subjects: 300
Study 38510748 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally relevant gratitude journaling intervention
Number of subjects: 26
Study 38510979 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft gelatin capsules containing polyunsaturated fatty acids (PUFAs) taken once daily for 12 months
Number of subjects: 20
Study 38510979 — intervention group
Group type: COMPARATOR
Intervention: Soft gelatin capsules containing olive oil (placebo)
Number of subjects: 20
Study 38510983 — intervention group
Group type: EXPERIMENTAL
Intervention: Vebicorvir (VBR) + Nucleos(t)ide Reverse Transcriptase Inhibitors (NrtIs)
Number of subjects: 92
Study 38511087 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous Ig20Gly (50-200 mg/kg) administered weekly for 24 weeks (Epoch 2)
Number of subjects: 17
Study 38511087 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous Ig20Gly (100-400 mg/kg) administered every 2 weeks for 12 weeks (Epoch 3)
Number of subjects: 17
Study 38511087 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment-emergent adverse events during Epochs 2 and 3
Number of subjects: 17
Study 38511555 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with CHB after BTI
Number of subjects: 101
Study 38511555 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (HCs) after BTI
Number of subjects: 101
Study 38511563 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobocertinib at 160 mg once daily
Number of subjects: 114
Study 38511563 — intervention group
Group type: COMPARATOR
Intervention: Mobocertinib
Number of subjects: 114
Study 38512023 — intervention group
Group type: EXPERIMENTAL
Intervention: 4D flow cardiac MRI with late gadolinium enhancement (LGE) in individuals with HCM
Number of subjects: 88
Study 38512023 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 88
Study 38512023 — intervention group
Group type: EXPERIMENTAL
Intervention: Cox proportional hazard model analysis
Number of subjects: 88
Study 38512294 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamified Strength Recognition and Quiz
Number of subjects: 0
Study 38512307 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-directed VEGA Family Violence Education Resources
Number of subjects: 105
Study 38512307 — intervention group
Group type: COMPARATOR
Intervention: Workshop VEGA Family Violence Education Resources
Number of subjects: 105
Study 38512333 — intervention group
Group type: EXPERIMENTAL
Intervention: DiaCert app (intervention group)
Number of subjects: 181
Study 38512333 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 181
Study 38512336 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based physical activity promotion intervention consisting of 4 web-based group workshops over 10 weeks, web-based tasks and resources, and a social support chat group
Number of subjects: 254
Study 38512336 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 254
Study 38512385 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypo-METRICS Smartphone Application
Number of subjects: 0
Study 38512387 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring (CGM)
Number of subjects: 0
Study 38512387 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal Insulin Switch
Number of subjects: 0
Study 38512619 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk- and breast density-stratified screening model (biennial DBT, annual DBT, ultrasound, breast MRI based on risk factors)
Number of subjects: 10469
Study 38512619 — intervention group
Group type: COMPARATOR
Intervention: Annual digital mammography (DM) screening
Number of subjects: 10469
Study 38512694 — intervention group
Group type: EXPERIMENTAL
Intervention: Vutrisiran (25 mg subcutaneous injection once every 3 months)
Number of subjects: 164
Study 38512694 — intervention group
Group type: COMPARATOR
Intervention: Patisiran (0.3 mg/kg intravenous infusion once every 3 weeks)
Number of subjects: 164
Study 38512694 — intervention group
Group type: COMPARATOR
Intervention: External placebo
Number of subjects: 164
Study 38512706 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonimmersive Virtual Reality
Number of subjects: 0
Study 38512706 — intervention group
Group type: EXPERIMENTAL
Intervention: Task-Oriented Circuit Training
Number of subjects: 0
Study 38512706 — intervention group
Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 0
Study 38512879 — intervention group
Group type: EXPERIMENTAL
Intervention: New passive ankle prosthesis with an articulated ankle joint
Number of subjects: 0
Study 38512879 — intervention group
Group type: COMPARATOR
Intervention: Standard passive prosthesis
Number of subjects: 0
Study 38512879 — intervention group
Group type: EXPERIMENTAL
Intervention: Both prosthetic types
Number of subjects: 0
Study 38512931 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-COVID-19 lockdown
Number of subjects: 0
Study 38512931 — intervention group
Group type: COMPARATOR
Intervention: Pre-COVID-19 lockdown
Number of subjects: 0
Study 38512958 — intervention group
Group type: EXPERIMENTAL
Intervention: Left posterior sacrospinous fixation (SSF)
Number of subjects: 1
Study 38512958 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral posterior sacrospinous fixation (SSF)
Number of subjects: 1
Study 38512958 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral posterior SSF with suture at 1 cm from ischial spine
Number of subjects: 1
Study 38512958 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral posterior SSF with suture at 3 cm from ischial spine
Number of subjects: 1
Study 38512958 — intervention group
Group type: EXPERIMENTAL
Intervention: Left SSF with suture at 1 cm from ischial spine
Number of subjects: 1
Study 38512958 — intervention group
Group type: EXPERIMENTAL
Intervention: Left SSF with suture at 3 cm from ischial spine
Number of subjects: 1
Study 38512960 — intervention group
Group type: COMPARATOR
Intervention: Delta variant infection (after 2 doses)
Number of subjects: 491
Study 38512960 — intervention group
Group type: EXPERIMENTAL
Intervention: Omicron BA.4/5 infection (after 3 doses)
Number of subjects: 491
Study 38512960 — intervention group
Group type: COMPARATOR
Intervention: Delta variant infection
Number of subjects: 491
Study 38512960 — intervention group
Group type: EXPERIMENTAL
Intervention: Omicron BA.4/5 infection
Number of subjects: 491
Study 38512960 — intervention group
Group type: EXPERIMENTAL
Intervention: Omicron sub-variants infections
Number of subjects: 491
Study 38512960 — intervention group
Group type: EXPERIMENTAL
Intervention: PCR Ct values in BA.1 infections
Number of subjects: 491
Study 38512960 — intervention group
Group type: EXPERIMENTAL
Intervention: Viral load trajectories and peaks
Number of subjects: 491
Study 38513060 — intervention group
Group type: EXPERIMENTAL
Intervention: Inorganic nitrate (12 mmol potassium nitrate once daily for 5 days)
Number of subjects: 640
Study 38513060 — intervention group
Group type: COMPARATOR
Intervention: Placebo (potassium chloride)
Number of subjects: 640
Study 38513170 — intervention group
Group type: EXPERIMENTAL
Intervention: PD-1/PD-L1 inhibitor-based therapy
Number of subjects: 625
Study 38513170 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 625
Study 38513188 — intervention group
Group type: COMPARATOR
Intervention: Fulvestrant (F)
Number of subjects: 220
Study 38513188 — intervention group
Group type: EXPERIMENTAL
Intervention: Fulvestrant plus Palbociclib (F + P)
Number of subjects: 220
Study 38513188 — intervention group
Group type: EXPERIMENTAL
Intervention: Fulvestrant plus Palbociclib and Avelumab (F + P + A)
Number of subjects: 220
Study 38513321 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative systolic blood pressure (SBP)
Number of subjects: 8282
Study 38513321 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline systolic blood pressure (SBP)
Number of subjects: 8282
Study 38513321 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional risk factors combined with cumulative SBP
Number of subjects: 8282
Study 38513321 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative blood pressure (BP)
Number of subjects: 8282
Study 38513321 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative pulse pressure
Number of subjects: 8282
Study 38513367 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity interval training (HIIT) combining rowing and cycling for 8 weeks
Number of subjects: 0
Study 38513367 — intervention group
Group type: COMPARATOR
Intervention: Control group (sedentary obese and lean individuals)
Number of subjects: 0
Study 38513367 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIT (all groups)
Number of subjects: 0
Study 38513368 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA-1273 (100-µg doses)
Number of subjects: 234
Study 38513368 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA-1273 (after dose 2)
Number of subjects: 234
Study 38513368 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA-1273 (after dose 3)
Number of subjects: 234
Study 38513368 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA-1273 (post-additional dose)
Number of subjects: 234
Study 38513368 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA-1273 (in kidney SOTRs)
Number of subjects: 234
Study 38513424 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurofeedback sessions (5 sessions)
Number of subjects: 15
Study 38513424 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurofeedback sessions (2 sessions)
Number of subjects: 15
Study 38513424 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurofeedback sessions (1 session)
Number of subjects: 15
Study 38513424 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurofeedback sessions (3 sessions)
Number of subjects: 15
Study 38513436 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab (150 mg biweekly)
Number of subjects: 139
Study 38513436 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 139
Study 38513436 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Alirocumab and Placebo)
Number of subjects: 139
Study 38513436 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab
Number of subjects: 139
Study 38513436 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab and Placebo
Number of subjects: 139
Study 38513683 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI-guided stereotactic ablative body radiotherapy (SABR) - five fractions of 8 Gy delivered on non-consecutive days
Number of subjects: 68
Study 38513683 — intervention group
Group type: COMPARATOR
Intervention: CT-guided percutaneous irreversible electroporation
Number of subjects: 68
Study 38513684 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-administered Na-GST-1 on Alhydrogel plus Na-APR-1(M74) on Alhydrogel and glucopyranosyl lipid A in aqueous formulation (GLA-AF)
Number of subjects: 60
Study 38513684 — intervention group
Group type: COMPARATOR
Intervention: Co-administered ENGERIX-B hepatitis B vaccine (HBV) and saline placebo
Number of subjects: 60
Study 38513689 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA-1273 (50 µg) booster vaccination and QIV co-administered (Coad group)
Number of subjects: 498
Study 38513689 — intervention group
Group type: COMPARATOR
Intervention: mRNA-1273 (50 µg) booster vaccination and QIV sequentially administered (Seq group)
Number of subjects: 498
Study 38513689 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Coad and Seq)
Number of subjects: 498
Study 38513746 — intervention group
Group type: EXPERIMENTAL
Intervention: Motion style acupuncture treatment (MSAT) combined with integrative Korean medicine (IKM)
Number of subjects: 96
Study 38513746 — intervention group
Group type: COMPARATOR
Intervention: Control group (IKM without MSAT)
Number of subjects: 96
Study 38513888 — intervention group
Group type: EXPERIMENTAL
Intervention: ω-3 FA supplement (DHA 0.8 g and EPA 1.7 g daily)
Number of subjects: 0
Study 38513888 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 38513982 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-MDM panel algorithm
Number of subjects: 125
Study 38514081 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-PD-1 inhibitors
Number of subjects: 0
Study 38514081 — intervention group
Group type: COMPARATOR
Intervention: Pathologic assessments of PD-L1 status
Number of subjects: 0
Study 38514101 — intervention group
Group type: EXPERIMENTAL
Intervention: Near-infrared angiography using indocyanine green and endoscopic fluorescence imaging
Number of subjects: 310
Study 38514101 — intervention group
Group type: COMPARATOR
Intervention: Standard intra-operative assessment (control arm)
Number of subjects: 310
Study 38514147 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancreatic endotherapy or surgery for clearance of painful pancreatic duct obstruction
Number of subjects: 150
Study 38514168 — intervention group
Group type: EXPERIMENTAL
Intervention: simplified rPAP respiratory support system
Number of subjects: 32
Study 38514306 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiological complete response (CR) at week 9
Number of subjects: 362
Study 38514306 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiological partial response (PR) at week 9
Number of subjects: 362
Study 38514306 — intervention group
Group type: COMPARATOR
Intervention: Stable disease (SD) at week 9
Number of subjects: 362
Study 38514519 — intervention group
Group type: EXPERIMENTAL
Intervention: Aortic global longitudinal strain (AOGLS)
Number of subjects: 194
Study 38514519 — intervention group
Group type: EXPERIMENTAL
Intervention: Low AOGLS <4.26%
Number of subjects: 194
Study 38514823 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive blood pressure control (n=205)
Number of subjects: 393
Study 38514823 — intervention group
Group type: COMPARATOR
Intervention: Standard blood pressure control (n=188)
Number of subjects: 393
Study 38514823 — intervention group
Group type: EXPERIMENTAL
Intervention: Preexisting CSD
Number of subjects: 393
Study 38514823 — intervention group
Group type: EXPERIMENTAL
Intervention: Age, male sex, and increased body mass index
Number of subjects: 393
Study 38514860 — intervention group
Group type: EXPERIMENTAL
Intervention: Wrist-worn digital health technology (DHT)
Number of subjects: 40
Study 38514860 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar-worn digital health technology (DHT)
Number of subjects: 40
Study 38514860 — intervention group
Group type: COMPARATOR
Intervention: Gait metrics from lumbar-worn DHT
Number of subjects: 40
Study 38514860 — intervention group
Group type: COMPARATOR
Intervention: Gait and physical activity metrics
Number of subjects: 40
Study 38515146 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced cross-sectoral collaboration and treatment during the first 3 months following diagnosis.
Number of subjects: 270
Study 38515149 — intervention group
Group type: EXPERIMENTAL
Intervention: Anlotinib-based therapy
Number of subjects: 14
Study 38515183 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir/lamivudine (DTG/3TC)
Number of subjects: 1234
Study 38515183 — intervention group
Group type: COMPARATOR
Intervention: Current antiretroviral regimen (CAR)
Number of subjects: 1234
Study 38515199 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacral neuromodulation (SNM) - invasive variant
Number of subjects: 0
Study 38515199 — intervention group
Group type: COMPARATOR
Intervention: Enteral neuromodulation (ENM) - non-invasive approach with adhesive electrodes
Number of subjects: 0
Study 38515201 — intervention group
Group type: EXPERIMENTAL
Intervention: Smart Speaker EchoDot 3rd Gen device (Amazon Echo®) for home use
Number of subjects: 112
Study 38515201 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 112
Study 38515275 — intervention group
Group type: EXPERIMENTAL
Intervention: DISC-0974 (7-56 mg, administered IV or SC)
Number of subjects: 42
Study 38515275 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 38515445 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognito's Evoked Gamma Therapy System (CogTx-001), self-administered daily for one hour over 6 months.
Number of subjects: 76
Study 38515445 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment, self-administered daily for one hour over 6 months.
Number of subjects: 76
Study 38515445 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognito's Evoked Gamma Therapy System (CogTx-001)
Number of subjects: 76
Study 38515445 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 76
Study 38515570 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg administered by intravenous infusion on day 1 every 3 weeks (Q3W)
Number of subjects: 30
Study 38515967 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal Management Training (GMT)
Number of subjects: 65
Study 38516099 — intervention group
Group type: EXPERIMENTAL
Intervention: Sintilimab 200 mg on day one and oral daily anlotinib 12 mg on days 1-14 once every three weeks per cycle
Number of subjects: 42
Study 38516099 — intervention group
Group type: EXPERIMENTAL
Intervention: Sintilimab plus anlotinib
Number of subjects: 42
Study 38516100 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine + Bromhexine
Number of subjects: 995
Study 38516100 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine + Cyproheptadine
Number of subjects: 995
Study 38516100 — intervention group
Group type: EXPERIMENTAL
Intervention: Niclosamide + Bromhexine
Number of subjects: 995
Study 38516100 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 995
Study 38516100 — intervention group
Group type: COMPARATOR
Intervention: Standard Care
Number of subjects: 995
Study 38516258 — intervention group
Group type: EXPERIMENTAL
Intervention: Nature-based VR intervention (Active VR arm)
Number of subjects: 109
Study 38516258 — intervention group
Group type: COMPARATOR
Intervention: Sham VR intervention (Sham VR arm)
Number of subjects: 109
Study 38516651 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-sampled hrHPV testing
Number of subjects: 0
Study 38516651 — intervention group
Group type: COMPARATOR
Intervention: Clinician-collected hrHPV tests
Number of subjects: 0
Study 38516817 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional connectivity (FC) in patients with NDPH
Number of subjects: 29
Study 38516817 — intervention group
Group type: COMPARATOR
Intervention: Functional connectivity (FC) in healthy controls (HCs)
Number of subjects: 29
Study 38517085 — intervention group
Group type: EXPERIMENTAL
Intervention: NEXUS criteria
Number of subjects: 21379
Study 38517085 — intervention group
Group type: EXPERIMENTAL
Intervention: Canadian C-Spine Rule
Number of subjects: 21379
Study 38517085 — intervention group
Group type: EXPERIMENTAL
Intervention: PECARN retrospective criteria
Number of subjects: 21379
Study 38517085 — intervention group
Group type: EXPERIMENTAL
Intervention: CG56 guideline
Number of subjects: 21379
Study 38517085 — intervention group
Group type: EXPERIMENTAL
Intervention: PEDSPINE criteria
Number of subjects: 21379
Study 38517235 — intervention group
Group type: EXPERIMENTAL
Intervention: Pralatrexate 25 mg/m²
Number of subjects: 0
Study 38517235 — intervention group
Group type: EXPERIMENTAL
Intervention: Romidepsin
Number of subjects: 0
Study 38517242 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra treatment
Number of subjects: 534
Study 38517242 — intervention group
Group type: COMPARATOR
Intervention: HBP levels higher than 35 ng/mL
Number of subjects: 534
Study 38517311 — intervention group
Group type: EXPERIMENTAL
Intervention: Smart glasses group
Number of subjects: 119
Study 38517311 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 119
Study 38517311 — intervention group
Group type: EXPERIMENTAL
Intervention: Anaesthesiology fellows (CA 5 years)
Number of subjects: 119
Study 38517366 — intervention group
Group type: EXPERIMENTAL
Intervention: Counterforce brace (CB)
Number of subjects: 37
Study 38517366 — intervention group
Group type: EXPERIMENTAL
Intervention: Wrist orthosis (WO)
Number of subjects: 37
Study 38517366 — intervention group
Group type: COMPARATOR
Intervention: No orthosis
Number of subjects: 37
Study 38517416 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib plus an aromatase inhibitor (AI)
Number of subjects: 0
Study 38517442 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-based coaching rehabilitation intervention delivered over 9 sessions.
Number of subjects: 303
Study 38517442 — intervention group
Group type: COMPARATOR
Intervention: Education-based attention control condition delivered via telephone at matched intervals.
Number of subjects: 303